10. June 2020

Naviswiss Wins FDA Clearance

Naviswiss has received FDA clearance for our new navigation technology for hip replacement surgery.  The clearance includes primary hip replacement and revision hip replacement surgery.  The system can be used with a variety of surgical approaches and most implants on the market.
With the recent FDA approval, Naviswiss is offering their products in all US Markets, looking to build upon their previous business in Europe, Australia and Asia.
There has been a need in the US for a mart, cost-effective solution for navigated hip replacements. There has still been a technology gap with the hip. We can now offer a simple, imageless solution to patients and healthcare providers, with the potential of reducing the rate of revisions as well as reducing radiation exposure.
Daniel Moore, Chief Commercial Officer, Naviswiss Inc.